What is Signatera™?
The Signatera™ test is highly sensitive. It is a personalised molecular residual tumour (MRT) test that uses circulating tumour DNA (ctDNA) in the blood for analysis. Signatera is designed individually for each patient to help identify tumour recurrence well before standard imaging procedures.
Molecular residual tumour is a different
By using the Signatera™ test, early detection of MRI has become an effective tool for improving cancer treatment outcomes.
How does Signatera™ work?
Signatera™ is a personalised, tumour-specific, MRI follow-up test. A single analysis of tissue and blood samples allows the determination of a unique tumour mutation profile.
The Signatera™ MRD test examines tiny pieces of ctDNA during each follow-up blood sample. Patients who test positive for ctDNA in the Signatera™ test are more likely to develop a worsening condition.
The applicability of the ctDNA test:
- Symptom-free cancer screening
- Molecular residual disease status
- Monitoring early relapse
- Monitoring the effectiveness of teraphy
Signatera has been validated for several tumour types
The Signatera™ test can be used for all somatic tumour types.
Signatera™ can help manage the care of patients with tumours
Risk
Useful results: colon tumour stage II-III
Interpretation of the test
ctDNA high risk
Use of direct imaging techniques (PET/MRI) to determine the location of the tumour while it is still operable
>97% of patients can have their tumour recur
ctDNA low risk
Continuing the monitoring
Between 12 and 14% of patients may have a recurrence. For patients who remain negative 2 years after treatment, the risk is reduced to 3%.